If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Quality, Compliance and Regulatory » Government Affairs and Public Policy
Download FREE Excerpt
10 Info Graphics
23 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
The Government Affairs and Public Policy functions play a vital and growing role in the biopharma sector given the increasing importance that reimbursement, regulatory and political issues play in an organization's overall success in the marketplace. Thus, it is essential for these groups to have resourcing and funding levels that enable effective and efficient operations. Likewise, effective Government Affairs and Public Policy groups have clearly established service levels, priorities, and responsibilities.
Best Practices, LLC undertook this study to identify the benchmarks of leading companies regarding the staffing, budgeting, service levels, and responsibilities of their Government Affairs and Public Policy groups.
Participants ranging from middle level management to senior executives at 15 leading bio-pharmaceutical, healthcare and medical device companies participated in the study. Field interviews and study analysis produced many observations and benchmark findings to reflect opportunities across the Public policy and Government Affairs function for organization growth and profitability.
Pharmaceutical; Health Care; Biotech; Chemical; Medical Device
Boehringer Ingelheim; Novo Nordisk; Abbott Laboratories; Genentech; AstraZeneca; Roche; UCB Pharma; GlaxoSmithKline; Solvay Pharmaceuticals; Stiefel; Pfizer; Lilly; Baxter International; Cephalon; Inc.; DRI; Biomarin